SHILPAMED — Shilpa Medicare Income Statement
0.000.00%
- IN₹66.28bn
- IN₹70.73bn
- IN₹11.52bn
- 79
- 13
- 73
- 59
Annual income statement for Shilpa Medicare, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9,079 | 9,011 | 11,455 | 10,501 | 11,516 |
Cost of Revenue | |||||
Gross Profit | 5,811 | 5,799 | 6,961 | 5,630 | 6,779 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,359 | 7,220 | 10,179 | 10,571 | 10,178 |
Operating Profit | 1,720 | 1,791 | 1,276 | -69.6 | 1,338 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,881 | 1,951 | 1,023 | -383 | 543 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,546 | 1,462 | 606 | -309 | 320 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,562 | 1,478 | 607 | -325 | 319 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,562 | 1,478 | 607 | -325 | 319 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 19.2 | 12.6 | 6.75 | -3.72 | 3.22 |
Dividends per Share |